Tassos is dedicated to taking on the world’s most challenging health problems, with a focus on cardiovascular disease. He is co-founder, CEO and chair of Kardigan, a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. Prior to Kardigan, Tassos served as chief executive officer of cardiovascular drug development company MyoKardia, which was acquired by Bristol Myers Squibb. He also co-founded cardiovascular technology and connected care company Prolaio, where he currently holds the role of chair and chief executive officer.